Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
Accepting patients
Talquetamab Consolidation After BCMA CAR-T
Talquetamab Consolidation After BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Post-CAR T
- Phase 2
Not currently accepting
CA057-003
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- CELMoD
- Phase 1/2
- Has results
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Accepting patients
MagnetisMM-20
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
MagnetisMM-5
Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
- Bispecific Antibody
- Phase 3
Accepting patients
SubQSA
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Monoclonal Antibody
- CD38
- Phase 2
Accepting patients
Etentamig with Iberdomide
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
- CELMoD
- Bispecific Antibody
- BCMA
- Phase 1
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
- Trispecific Antibody
- BCMA
- GPRC5D
- Phase 1
- Has results
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific T Cell Engager (BiTE)
- Bispecific Antibody
- CD3
- BCMA
- Phase 1
- Has results
Accepting patients
Elranatamab + Cyclophosphamide
Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
- Chemotherapy
- Bispecific Antibody
- BCMA
- Phase 2
4 hidden based on your filters.Show All